Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California.
Department of Pathology, University of Giessen, Giessen, Germany.
Am J Respir Crit Care Med. 2020 Jan 15;201(2):148-157. doi: 10.1164/rccm.201903-0656CI.
Pulmonary arterial hypertension (PAH) is a disease characterized by progressive loss and remodeling of the pulmonary arteries, resulting in right heart failure and death. Until recently, PAH was seen as a disease restricted to the pulmonary circulation. However, there is growing evidence that patients with PAH also exhibit systemic vascular dysfunction, as evidenced by impaired brachial artery flow-mediated dilation, abnormal cerebral blood flow, skeletal myopathy, and intrinsic kidney disease. Although some of these anomalies are partially due to right ventricular insufficiency, recent data support a mechanistic link to the genetic and molecular events behind PAH pathogenesis. This review serves as an introduction to the major systemic findings in PAH and the evidence that supports a common mechanistic link with PAH pathophysiology. In addition, it discusses recent studies describing morphological changes in systemic vessels and the possible role of bronchopulmonary anastomoses in the development of plexogenic arteriopathy. On the basis of available evidence, we propose a paradigm in which metabolic abnormalities, genetic injury, and systemic vascular dysfunction contribute to systemic manifestations in PAH. This concept not only opens exciting research possibilities but also encourages clinicians to consider extrapulmonary manifestations in their management of patients with PAH.
肺动脉高压(PAH)是一种以肺血管进行性丧失和重塑为特征的疾病,可导致右心衰竭和死亡。直到最近,PAH 被认为是一种仅限于肺循环的疾病。然而,越来越多的证据表明,PAH 患者还表现出系统性血管功能障碍,表现为肱动脉血流介导的扩张受损、脑血流异常、骨骼肌病和内在肾脏疾病。尽管其中一些异常部分是由于右心室功能不全引起的,但最近的数据支持与 PAH 发病机制背后的遗传和分子事件存在机制联系。本综述介绍了 PAH 的主要系统性发现以及支持与 PAH 病理生理学存在共同机制联系的证据。此外,它还讨论了最近描述系统性血管形态变化的研究以及支气管肺吻合术在丛状动脉病发展中的可能作用。基于现有证据,我们提出了一个假说,即代谢异常、遗传损伤和系统性血管功能障碍导致 PAH 的全身表现。这一概念不仅开辟了令人兴奋的研究可能性,也促使临床医生在管理 PAH 患者时考虑到肺外表现。